These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17016152)

  • 21. Donepezil for Alzheimer's disease.
    Benjamin B; Burns A
    Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced magnetic auditory steady-state response in early Alzheimer's disease.
    Osipova D; Pekkonen E; Ahveninen J
    Clin Neurophysiol; 2006 Sep; 117(9):1990-5. PubMed ID: 16887381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sensory gating P50 in schizophrenic patients with and without homicide].
    Wang HX; Zhen WF; Ma X; Wang YP; Tian JH; Dou QS; Zhao HX
    Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2616-20. PubMed ID: 20137678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholinergic gating of hippocampal auditory evoked potentials in freely moving rats.
    Klinkenberg I; Sambeth A; Blokland A
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):988-97. PubMed ID: 22974558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do lesions involving the cortical cholinergic pathways help or hinder efficacy of donepezil in patients with Alzheimer's disease?
    Fukui T; Hieda S; Bocti C
    Dement Geriatr Cogn Disord; 2006; 22(5-6):421-31. PubMed ID: 16974095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients.
    Chen XS; Li CB; Smith RC; Xiao ZP; Wang JJ
    Psychiatry Res; 2011 Aug; 188(3):327-33. PubMed ID: 21216472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia.
    Myles-Worsley M; Ord L; Blailes F; Ngiralmau H; Freedman R
    Biol Psychiatry; 2004 Apr; 55(7):663-7. PubMed ID: 15038993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients.
    Vaitkevičius A; Kaubrys G; Audronytė E
    Med Sci Monit; 2015 Jul; 21():1920-7. PubMed ID: 26138001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Auditory sensory memory and the cholinergic system: implications for Alzheimer's disease.
    Pekkonen E; Hirvonen J; Jääskeläinen IP; Kaakkola S; Huttunen J
    Neuroimage; 2001 Aug; 14(2):376-82. PubMed ID: 11467911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive predictors of donepezil therapy response in Alzheimer disease.
    Saumier D; Murtha S; Bergman H; Phillips N; Whitehead V; Chertkow H
    Dement Geriatr Cogn Disord; 2007; 24(1):28-35. PubMed ID: 17495473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A follow-up study on features of sensory gating P50 in treatment-resistant depression patients.
    Wang Y; Fang YR; Chen XS; Chen J; Wu ZG; Yuan CM; Yi ZH; Hong W; Zhang C; Cao L
    Chin Med J (Engl); 2009 Dec; 122(24):2956-60. PubMed ID: 20137481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease.
    Jessen F; Kucharski C; Fries T; Papassotiropoulos A; Hoenig K; Maier W; Heun R
    Am J Psychiatry; 2001 Aug; 158(8):1319-21. PubMed ID: 11481170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deficits in auditory P50 inhibition in obsessive-compulsive disorder.
    Hashimoto T; Shimizu E; Koike K; Orita Y; Suzuki T; Kanahara N; Matsuzawa D; Fukami G; Miyatake R; Shinoda N; Fujisaki M; Shirayama Y; Hashimoto K; Iyo M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):288-96. PubMed ID: 17884267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P50 gating at acute and post-acute phases of first-episode schizophrenia.
    Devrim-Uçok M; Keskin-Ergen HY; Uçok A
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1952-6. PubMed ID: 18929611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of age on sensory gating of the sleep state-dependent P1/P50 midlatency auditory evoked potential.
    Rasco L; Skinner RD; Garcia-Rill E
    Sleep Res Online; 2000; 3(3):97-105. PubMed ID: 11382907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cortical correlates of auditory sensory gating: a simultaneous near-infrared spectroscopy event-related potential study.
    Ehlis AC; Ringel TM; Plichta MM; Richter MM; Herrmann MJ; Fallgatter AJ
    Neuroscience; 2009 Mar; 159(3):1032-43. PubMed ID: 19356687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic effects of cannabis on sensory gating.
    Broyd SJ; Greenwood LM; Croft RJ; Dalecki A; Todd J; Michie PT; Johnstone SJ; Solowij N
    Int J Psychophysiol; 2013 Sep; 89(3):381-9. PubMed ID: 23628289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of donepezil on EEG spectral analysis in Alzheimer's disease.
    Balkan S; Yaraş N; Mihçi E; Dora B; Ağar A; Yargiçoğlu P
    Acta Neurol Belg; 2003 Sep; 103(3):164-9. PubMed ID: 14626697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.